France Genetic Testing Market Outlook to 2024

Published : Nov-2017

No. of Pages : 54

order by fax Inquire before Buying request discount

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Introduction 5
2.1 What Is This Report About? 5
2.2 Genetic Testing Market Segmentation 5
2.3 Definitions of Markets Covered in the Report 6
3 Genetic Testing Market, France 7
3.1 Genetic Testing Market, France, Revenue ($m), 2010-2017 7
3.2 Genetic Testing Market, France, Revenue ($m), 2017-2024 9
3.3 Genetic Testing Market, France, Distribution Share by Revenue ($m), 2017 11
3.4 Genetic Testing Market, France, Company Share by Revenue ($m), 2017 12
4 Overview of Key Companies in France, Genetic Testing Market 14
4.1 F. Hoffmann-La Roche Ltd 14
4.1.1 Company Overview 14
4.2 PerkinElmer Inc 14
4.2.1 Company Overview 14
4.3 Abbott Laboratories 14
4.3.1 Company Overview 14
4.4 Qiagen NV 14
4.4.1 Company Overview 14
4.5 Hologic Inc 15
4.5.1 Company Overview 15
4.6 Myriad Genetics Inc 15
4.6.1 Company Overview 15
5 Genetic Testing Market Pipeline Products 16
6 Financial Deals Landscape 18
6.1 Equity Offerings 18
6.1.1 IntegraGen Raises USD4 Million in Private Placement of Shares 18
6.1.2 Diaxonhit to Raise USD9.5 Million in public offering of shares 19
6.2 Partnerships 20
6.2.1 Lucigen Enters into Distribution Agreement with Illumina 20
6.3 Private Equity 21
6.3.1 PAI Partners to Acquire ELITech from Ergon Capital Partners 21
6.4 Venture Financing 22
6.4.1 DNA Script Raises USD13.2 Million in Series A Financing 22
7 Recent Developments 23
7.1 Corporate Communications 23
7.1.1 Nov 29, 2016: Dosisoft Announces The Official Release (CE Marking) Of Epibeam, Its Pre-treatment QA Solution 23
7.1.2 Nov 28, 2016: MEDICREA Achieves Personalized Spine Milestone with 1,000 Patient-Specific UNiD Rod Procedures 24
7.1.3 Nov 07, 2016: Pierre Boulud appointed Corporate Vice Presidentof the Asia Pacific region at bioMerieux 24
7.1.4 Nov 02, 2016: Advanced Accelerator Applications Announces Swiss Marketing Authorization for AAACholine 25
7.2 Financial Announcements 25
7.2.1 Oct 24, 2017: Genomic Vision: Revenue from Sales for the First 9 Months of 2017 up 103% to 1.3 Million 25
7.2.2 Aug 30, 2017: bioMerieux - First-Half 2017 Results 26
7.2.3 Jul 25, 2017: Genomic Vision: First half 2017 results 28
7.2.4 Jul 20, 2017: bioMerieux - Second-Quarter 2017 Business Review 30
7.2.5 Jul 11, 2017: Integragen Reports Continued Growth During 1st Half Of 2017 31
7.2.6 May 09, 2017: Genomic Vision: Financial Information at March 31, 2017 32
7.2.7 Apr 21, 2017: IntegraGen Announces 2016 Annual Results: Increase in operating revenues and significant improvement in operating income (+22%) 33
7.2.8 Apr 20, 2017: bioMerieux - First-Quarter 2017 Business Review 34
7.2.9 Mar 01, 2017: Genomic Vision: 2016 Annual Results 36
7.2.10 Mar 01, 2017: bioMerieux - 2016 Financial Results 38
7.2.11 Jan 19, 2017: bioMerieux - Fourth-Quarter 2016 Business Review 40
7.2.12 Jan 09, 2017: IntegraGen Reports Sharp Increase in Sales During 2016 42
7.3 Other Significant Developments 43
7.3.1 Oct 18, 2017: bioMerieux - Business review for the nine months ended September 30, 2017 43
7.3.2 Jul 12, 2017: Genomic Vision: The Cologne Center for Genetics, a Major European Core Facility in Genetic Analysis, Adopts the Molecular Combing Technology 45
7.3.3 Jan 09, 2017: Genomic Vision Doubles Its Installed Base of FiberVision Platforms and Quadruples Its Sales of Products and Services in 2016 45
7.4 Product News 46
7.4.1 Jul 27, 2017: Genomic Vision: Molecular Combing Featured in an Oral Presentation on CRISPR/Cas9 Gene Editing at the 3rd CSHL Meeting in New York 46
7.4.2 Jun 09, 2017: Routine Molecular Screening of Advanced Refractory Cancer Patients 46
8 Appendix 48
8.1 Research Methodology 49
8.1.1 Coverage 49
8.1.2 Secondary Research 49
8.1.3 Primary Research 50
8.1.4 Market Modeling and Forecasting 51
8.1.5 Company Share Analysis 52
8.1.6 Distribution Share Analysis 53
8.1.7 Benchmarking 53
8.2 GlobalData Consulting 53
8.3 Contact Us 54
8.4 Disclaimer 54

1.1 List of Tables
Table 1: Genetic Testing Market, France, Revenue ($m), USD Constant, Historic, 2010-2017 8
Table 2: Genetic Testing Market, France, Revenue ($m), USD Constant, Forecast, 2017-2024 10
Table 3: Genetic Testing Market, France, Distribution Share by Revenue ($m), USD Constant, 2017 11
Table 4: Genetic Testing Market, France, Company Share by Revenue ($m), USD Constant, 2017 13
Table 5: Genetic Testing Market Pipeline Products 16
Table 6: IntegraGen Raises USD4 Million in Private Placement of Shares 18
Table 7: Diaxonhit to Raise USD9.5 Million in public offering of shares 19
Table 8: Lucigen Enters into Distribution Agreement with Illumina 20
Table 9: PAI Partners to Acquire ELITech from Ergon Capital Partners 21
Table 10: DNA Script Raises USD13.2 Million in Series A Financing 22
Table 11: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country 51

1.2 List of Figures
Figure 1: Genetic Testing Market, France, Revenue ($m), USD Constant, Historic, 2010-2017 7
Figure 2: Genetic Testing Market, France, Revenue ($m), USD Constant, Forecast, 2017-2024 9
Figure 3: Genetic Testing Market, France, Company Share (%) 2017 12

Filed in: In Vitro Diagnostic, Medical Device

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
In Vitro Fertilization /IVF Market by Product (Micromanipulators, Incubators, Cabinets, Imaging System, Laser System, Reagents & Accessories), Type (Conventional IVF, IVF with ICSI), End User (Fertility Clinics, Hospitals, Cryobanks) – Global Forecast to 2026 “The global in vitro fertilization market size is projected to reach USD 987 million by 2026 from USD 638 million in 2021, at a CAGR of 9.1 % during the forecast period” The global in vitro fertilization market is projected to reach USD 987 million by 2026 from USD 638 million in 2021, at a CAGR of 9.1% from 2021 to 2026. The key factors fueling the growth of this market include an increase in the median age of first-time mothers, declining fertility rates, rising male infertility, rise in obesity rate and growing consumption of alcohol, and growing awareness about the availability of treatment options. However, the high cost and low success rate of IVF treatment and restrictive regulations and ethical concerns are expected to restrict the growth of the IVF market to a certain e......	$4950
Assisted Reproductive Technology Devices (General Surgery) – Global Market Analysis and Forecast Model (COVID-19 market impact) Assisted Reproductive Technology Devices (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 market impact) Summary Assisted Reproductive Technology Devices (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within General Surgery therapeutic area. The model discusses in detail the impact of COVID-19 on Assisted Reproductive Technology Devices market for the year 2020 and beyond. Assisted Reproductive Technology (ART) refers to reproductive health procedures that treat infertile women to achieve pregnancy. For decades now across much of the developed world, several techniques of ART have been in use with varying pregnancy success rates. These techniques primarily include, but are no......	$7500
Multiparameter CT/NG NAAT Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 Market Impact) Multiparameter CT/NG NAAT Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) Summary Multiparameter CT/NG NAAT Tests (In Vitro Diagnostics) - Global Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. The model discusses in detail the impact of COVID-19 on Multiparameter CT/NG NAAT Tests market for the year 2020 and beyond. Chlamydia is a common sexually transmissible disease, caused by the bacteria Chlamydia Trachomatis. In women, Chlamydia Trachomatis infections are often asymptomatic, however, if left untreated they can cause pelvic inflammatory disease (PID), which in turn can lead to additional complications such as infertility, ectopic preg......	$7500
Hemophilia A and B – Global Drug Forecast and Market Analysis to 2028 Hemophilia A and B - Global Drug Forecast and Market Analysis to 2028 Summary Hemophilia A and B are rare, genetic, X-linked deficiencies in the blood clotting factors VIII (FVIII) and IX (FIX), respectively. Patients can be categorized as mild, moderate or severe depending on the percentage of circulating FVIII or FIX in their blood. Patients can be treated either on-demand or prophylactically using plasma-derived or recombinant replacement factors, the current standard of care. Although these therapies are effective, they are associated with a great treatment burden. There is a significant unmet need for new therapies that can reduce the great treatment burden associated with intravenous administration, the frequency of prophylactic infusions, and the risk of developing neutralizing a......	$10995
Human Immunodeficiency Virus (HIV) Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model Human Immunodeficiency Virus (HIV) Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model Summary Human Immunodeficiency Virus (HIV) Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Human Immunodeficiency Virus (HIV) has become one of the world's most serious health issues affecting approximately 36.9 million people. The epidemiology of HIV infections varies from one geographical region to another. Sources indicate that in many countries, incidence rates for HIV have stabilized due to the campaigns that provide condoms, pre-exposure prophylaxis, sterile needles, syringes, antiretroviral therapy (ART), and prevention of mother-to-child transmission interv......	$7500
Chlamydia Trachomatis Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model Chlamydia Trachomatis Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model Summary Chlamydia Trachomatis Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Chlamydia is a common sexually transmissible disease, caused by the bacteria Chlamydia trachomatis. Patient access to Chlamydia screening, and thus the number of reported cases, varies substantially between countries. In some countries annual screening is recommended for specific patient groups deemed to be at higher risk of contracting the disease, such as sexually active females younger than 25 years. Additionally, screening of pregnant women for Chlamydia Trachomatis infections is currently recomme......	$7500
EGFR Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model EGFR Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model Summary EGFR Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Globally, lung cancer is the second most common cancer in men and the third most common cancer in women. There are two main types of lung cancer; small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with NSCLC accounting for approximately 80-90% of all lung cancer cases. The 5-year survival rate for patients with stage IV disease is less than 5% as majority of patients present with the advanced or metastatic disease at diagnosis. EGFR is a member of the receptor tyrosine kinase family and a major factor in regulating ......	$7500
Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Cervical cancer screening has traditionally been based on cervical cytology. In recent years however, many countries have incorporated Human Papilloma Virus (HPV) tests into their cervical cancer and pre-cancer screening programs. Cytology based screening programs require a well-established healthcare infrastructure for processing and interpretation of samples. It is hoped that HPV screening methods may enable better prevention of these disease, these devices are also highly sensitive an......	$7500
Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model "Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Cytomegalovirus (CMV) represents the most common congenital, viral infection in the developed world and awareness of this disease is increasing. Few countries have official guidelines in place for CMV screening but in general testing tends to be performed for sperm donations, immunocompromised cases, and pregnant women. Diagnosis of CMV infections is complex as symptoms are often non-specific and mimic mononucleosis or the flu. Approximately 21-25% of primary CMV infections are symptomatic ......	$7500
Human T-Lymphotropic Virus (HTLV) Test (In Vitro Diagnostics) – Global Market Analysis and Forecast Model Human T-Lymphotropic Virus (HTLV) Test (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Human T-Lymphotropic Virus (HTLV) Test (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Human T-Lymphotropic Virus (HTLV) is a retrovirus that infects T Lymphocyte cells. There are four strains of HTLV, out of these HTLV-I and HTLV-II are the most prevalent. HTLV-I is the causative agent of two severe neurological diseases. Specifically, sources indicate that up to 3-5% of patients infected with HTLV-I develop adult T-cell Leukemia/Lymphoma (ATLL) or HTLV-I-associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP). Conversely, HTLV-II has been linked to elevate......	$7500

France Genetic Testing Market Outlook to 2024

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

In Vitro Fertilization /IVF Market by Product (Micromanipulators, Incubators, Cabinets, Imaging System, Laser System, Reagents & Accessories), Type (Conventional IVF, IVF with ICSI), End User (Fertility Clinics, Hospitals, Cryobanks) – Global Forecast to 2026

Assisted Reproductive Technology Devices (General Surgery) – Global Market Analysis and Forecast Model (COVID-19 market impact)

Multiparameter CT/NG NAAT Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 Market Impact)

Hemophilia A and B – Global Drug Forecast and Market Analysis to 2028

Human Immunodeficiency Virus (HIV) Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model

Chlamydia Trachomatis Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model

EGFR Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model

Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model

Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model

Human T-Lymphotropic Virus (HTLV) Test (In Vitro Diagnostics) – Global Market Analysis and Forecast Model